VKH
CBAY

Virtu KCG Holdings’s Cymabay Therapeutics CBAY Stock Holding History

Virtu KCG Holdings’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,208
Closed -$33K – 3892
2016
Q3 		$33K Buy
+17,208
New +$34.2K ﹤0.01% 2858
2016
Q1 		– Sell
-18,946
Closed -$32K – 3822
2015
Q4 		$32K Sell
18,946
-3,694
-16% -$6.02K ﹤0.01% 3239
2015
Q3 		$44K Buy
+22,640
New +$61.6K ﹤0.01% 3019

Other funds holding CBAY

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Virtu KCG Holdings's CBAY Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Cymabay Therapeutics (CBAY) in Q4 2016, closing a stake of 17,208 shares — an estimated $33K sold.

Virtu KCG Holdings first reported a position in CBAY in Q3 2015 and held it in 3 quarters. The position peaked at $44K in Q3 2015. 27 funds tracked by Wall St. Rank hold CBAY as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Cymabay Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 17,208 Cymabay Therapeutics shares in Q4 2016, an estimated $33K.
  • Virtu KCG Holdings first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 3 quarters.
  • Virtu KCG Holdings's Cymabay Therapeutics position peaked at $44K in Q3 2015.
  • 27 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.